Preventing Low Platelet Counts During Breast Cancer Chemotherapy
Part of Blood & lymphatic, Cancer, Skin clinical trials.
This study tests a medication called eltrombopag to help prevent dangerously low platelet counts (blood cells that help clotting) in breast cancer patients receiving chemotherapy. Low platelets can cause bleeding problems, and this drug may help keep your counts safer during treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with breast cancer confirmed by biopsy
- You are receiving or will receive chemotherapy lasting at least 21 days between treatments, with at least 2 planned cycles
- Your platelet count dropped below 50,000 in a previous chemo cycle, OR dropped to 50,000–75,000 with bleeding risk factors
- Your platelet count is currently at least 100,000 at the time you join the study
- Your liver, kidney, and bone marrow function are adequate (specific blood test results)
- You are not pregnant, breastfeeding, or unwilling to use birth control during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if hetrombopag can prevent low platelet counts caused by chemotherapy in people with gastrointestinal cancers. It may help reduce the risk of bleeding and the need for platelet transfusions.
This trial tests a drug called Hetrombopag to see if it can prevent low platelet counts in people with advanced lung cancer who are receiving certain types of chemotherapy. The goal is to help keep platelet levels safe so you can continue your cancer treatment without delays or dose reductions.
This trial tests a drug called hetrombopag to help raise platelet counts in women whose cancer therapy has caused low platelets. The goal is to see if it can safely prevent the need for platelet transfusions.
This Phase 2 study tests eltrombopag to help people with low platelet counts caused by chemotherapy (which can increase bleeding risk). It looks at whether raising platelets can reduce bleeding problems and help you stay on track with care.
This study tests if a combination of two medications, hetrombopag (a pill) and rhTPO (an injection), can safely raise very low platelet counts in people with solid tumors caused by their cancer treatments. If you have low platelets due to chemo, radiation, or other therapies, this may offer a new option.
This trial tests a drug called hetrombopag to see if it can prevent low platelet counts caused by antibody-drug conjugate (ADC) chemotherapy in breast cancer patients. It may help you avoid treatment delays or dose reductions.
Hear when a new Breast Cancer Patients at High Risk of Chemotherapy-induced Thrombocytopenia (CTIT) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.